melanoma – Talk Bio

IO Biotech’s cancer vaccine Cylembio narrowly misses Phase III primary endpoint in advanced melanoma, but company eyes FDA filing in 2025

2 weeks ago talkbio0Tagged biotech, Blackfoot language, Clinical Trials, Cylembio, Drops - Drug Form, etimupepimut, Hazard Ratio, Io satellite, Keytruda, melanoma, Overall Survival, P-Value, pembrolizumab, Phase 3, Progression-Free Survival, United States Food and Drug Administration

Cylembio; IO Biotech; melanoma; Phase 3; pivotal trial; progression-free survival (PFS); hazard ratio 0.77; p-value 0.056; Keytruda (pembrolizumab); FDA BLA; overall survival (OS) trend; IOB-013/KN-D18; NCT05155254; imsapepimut; etimupepimut; stock drop

Scientists Protest FDA’s Rejection of Replimune’s Tumor Destroying Therapy

3 weeks ago talkbio0Tagged Clinical Trials, Drug Approval, Heterogeneity, IGYNTE, melanoma, Oncolytic Immunotherapy, Rejection, Replimune, RETINITIS PIGMENTOSA 1, scientist protest, United States Food and Drug Administration

Replimune; RP1; FDA rejection; oncolytic immunotherapy; melanoma; clinical trial; IGYNTE study; scientist protest; drug approval; patient heterogeneity

Scancell’s Cancer Vaccine Supercharges Melanoma Immunotherapy in Recent Trials

1 month ago talkbio0Tagged Cancer Vaccines, checkpoint inhibitors, Clinical Trials, Immunotherapy, iSCIB1 +, melanoma, Melanoma TRP2 CTL Epitope Vaccine SCIB1, Scancell, SCOPE trial

Scancell; SCIB1; iSCIB1+; melanoma; cancer vaccine; immunotherapy; checkpoint inhibitors; clinical trial; SCOPE trial

Replimune’s Shares Plunge After FDA Rejects Melanoma Drug Application

1 month ago talkbio0Tagged Antineoplastic Agents, Clinical Trial Design, Complete, Drops - Drug Form, Frequency of Responses, melanoma, Prices, Rejection, Replimune, Response Letter, RETINITIS PIGMENTOSA 1, United States Food and Drug Administration

Replimune; RP1; FDA rejection; melanoma; cancer drug; Complete Response Letter; clinical trial design; objective response rate; share price drop

Bristol Myers Squibb’s Opdualag Fails Phase 3 Trial in Adjuvant Melanoma Treatment

6 months ago talkbio0Tagged Clinical Trials, Failure (biologic function), Immunologic Adjuvants, Immunotherapy, Inhibitor, lymphocyte-activation gene 3 protein, human, melanoma, Myers, Opdualag, squibb

Opdualag, Bristol Myers Squibb, melanoma, clinical trial failure, LAG-3 inhibitor, immunotherapy, adjuvant treatment

Immatics Advances Melanoma T-Cell Therapy into Late-Stage Clinical Trials

11 months ago talkbio0Tagged Immatics, Late stage, melanoma, Phase 3 trial, SUPRAME, T-cell therapy

Immatics, melanoma, T-cell therapy, ACTengine IMA203, late-stage clinical trials, SUPRAME Phase 3 trial

BioNTech and Regeneron Achieve Significant Response Rate Success in Phase 2 Trial for mRNA Cancer Immunotherapy BNT111

1 year ago talkbio0Tagged BioNTech, Cancer Therapeutic Procedure, cemiplimab, checkpoint inhibitor, melanoma, mRNA immunotherapy, mRNA-LPX technology, PDCD1 gene, Phase 2 trial, Regeneron, Tetravalent RNA-lipoplex Cancer Vaccine BNT111, uridine

BioNTech, Regeneron, mRNA immunotherapy, BNT111, Phase 2 trial, melanoma, cancer treatment, PD-1 checkpoint inhibitor, cemiplimab, FixVac platform, uridine mRNA-LPX technology